← Eichor
Condition: Primary Central Nervous System Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Primary Central Nervous System Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Phase 1/Phase 2 · 1 location(s) · James Rubenstein · NCT05351593A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07137494Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Phase 1 · 55 location(s) · National Cancer Institute (NCI) · NCT04609046Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Phase 1/Phase 2 · 5 location(s) · Tong Chen, MD · NCT05698147Cognitive Screening Made Easy for PCPs - Administrative Supplement
NA · 3 location(s) · University of Texas at Austin · NCT06928298A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplan
Phase 2 · 40 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015242The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma
Phase N/A · 1 location(s) · Vinodh Kakkassery, MD · NCT05841914Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Phase 2/Phase 3 · 1 location(s) · Navy General Hospital, Beijing · NCT02836158At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)
Phase N/A · 5 location(s) · Nordic Lymphoma Group · NCT06755619Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Parti
Phase 2 · 7 location(s) · Providence Health & Services · NCT06175000A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primar
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06556199Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03702309Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT05011045Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
Phase 1 · 1 location(s) · James Rubenstein · NCT04656431Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Phase 4 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT05518383SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ
NA · 1 location(s) · Ruijin Hospital · NCT07191431Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07416890IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma
Phase 3 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT07104032DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Phase 2 · 1 location(s) · Beijing Sanbo Brain Hospital · NCT04070040Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NA · 1 location(s) · Zhejiang Cancer Hospital · NCT06832267Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNS
Phase 3 · 35 location(s) · University Hospital Freiburg · NCT06830421Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05209620Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Phase 2 · 8 location(s) · Canadian Cancer Trials Group · NCT05998642A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Phase 1 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT07082868Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
Phase 2 · 1 location(s) · Seoul National University Bundang Hospital · NCT05260619
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.